Aventis Taxotere first-line indication
This article was originally published in Pharmaceutical Approvals Monthly
Aventis Taxotere (docetaxel) receives approval Nov. 27 for first-line treatment of patients with unresectable locally advanced or metastatic non-small cell lung cancer in combination with cisplatin. Approval is based on a 1,218-patient clinical trial comparing Taxotere plus cisplatin or Taxotere plus carboplatin to a standard vinorelbine/cisplatin regimen. Median survival time for Taxotere/cisplatin was 10.9 months versus 10.0 months with the standard regimen. Taxotere/cisplatin yielded a 31.6% overall response compared to 24.4% for standard therap
You may also be interested in...
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.
The withdrawal of the marketing authorization application for Dexamethasone Taw as a treatment for COVID-19 patients was revealed today in the January meeting agenda of the European Medicines Agency’s human medicines committee, the CHMP.